



CHEPLAPHARM SIGNED DEAL

Greifswald, 13/10/2021

This week Cheplapharm agreed with Sanofi on an asset-deal of 10 established products. The portfolio consists of three corticosteroids, one topic antibiotic and one combination of topic antibiotic and corticosteroid. It is distributed in more than 15 countries, including Egypt, Mexico and France. The closing of the transaction is scheduled for the first quarter 2022.

The APIs of the referring products are Prednisolone (as NA Methylsulpho Benzoate, NA Phosphate and Acetate), Deflazacort, Prednisone, Framycetin Sulfate (and also in combination with Gramicidin and Dexamethasone). The registered brand names of the products in this portfolio are Deflazacort®/Calcort®/Flantadin®, Otodex®/Soframycin®, Sofradex®/Sofracort®, Hydrocortancyl®, Solupred® and Cortancyl®/Prednisona®. The product name varies depending on the country in which it is marketed.

The transaction includes product registrations, intellectual property, certain contracts and inventory. The deal does not include any transfer of manufacturing facilities or employees.

About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe.

Please refer to www.cheplapharm.com for additional information.

Press office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)